Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D001792:Blood Platelets; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use; D006400:Hematocrit; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012156:Reticulocytes; D013997:Time Factors
D000970:Antineoplastic Agents; D005960:Glucosides; D011034:Podophyllotoxin